Ikena Oncology Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
9
- Latest Deal Type
-
M&A
Ikena Oncology General Information
Description
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
Contact Information
Website
www.ikenaoncology.comCorporate Office
- 645 Summer Street
- Suite 101
- Boston, MA 02210
- United States
Corporate Office
- 645 Summer Street
- Suite 101
- Boston, MA 02210
- United States
Ikena Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 25-Jul-2025 | Completed | Generating Revenue | |||
| 5. IPO | 26-Mar-2021 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B) | 05-Jan-2021 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC | 18-Jan-2019 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 14-Dec-2017 | $49M | $49M | Completed | Pre-Clinical Trials | |
| 1. Accelerator/Incubator | 14-Apr-2017 | Completed | Pre-Clinical Trials |
Ikena Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A2 | ||||||||
| Series A1 | 47,727,268 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 20.86% |
| Series A | 28,000,000 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 12.24% |
Ikena Oncology Comparisons
Industry
Financing
Details
Ikena Oncology Competitors (41)
One of Ikena Oncology’s 41 competitors is SpringWorks Therapeutics, a Formerly VC-backed company based in Stamford, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| SpringWorks Therapeutics | Formerly VC-backed | Stamford, CT | ||||
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| AVEO Oncology | Formerly VC-backed | Boston, MA |
Ikena Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ikena Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ikena Oncology Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Atlas Venture | Venture Capital | Minority | ||
| BVF Partners | Hedge Fund | Minority | ||
| Bristol-Myers Squibb | Corporation | Minority | ||
| Celgene | Corporation | Minority | ||
| Citadel Enterprise Americas | Hedge Fund | Minority |
Ikena Oncology Acquisitions (4)
Ikena Oncology’s most recent deal was a Reverse Merger with ImageneBio for . The deal was made on 25-Jul-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ImageneBio | 25-Jul-2025 | Reverse Merger | Drug Discovery | ||
| Pionyr Immunotherapeutics | 04-Aug-2023 | Merger/Acquisition | Drug Discovery | ||
| Amplify Medicines | 01-Oct-2020 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Arrys Therapeutics | 01-Dec-2018 | Merger/Acquisition | Drug Discovery |
Ikena Oncology ESG
Risk Overview
Risk Rating
Updated August, 31, 2025
37.75 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,999
Rank
Percentile
Pharmaceuticals
Industry
of 952
Rank
Percentile
Biotechnology
Subindustry
of 444
Rank
Percentile
Ikena Oncology FAQs
-
When was Ikena Oncology founded?
Ikena Oncology was founded in 2016.
-
Where is Ikena Oncology headquartered?
Ikena Oncology is headquartered in Boston, MA.
-
What is the size of Ikena Oncology?
Ikena Oncology has 9 total employees.
-
What industry is Ikena Oncology in?
Ikena Oncology’s primary industry is Drug Discovery.
-
Is Ikena Oncology a private or public company?
Ikena Oncology is a Private company.
-
What is Ikena Oncology’s current revenue?
The current revenue for Ikena Oncology is .
-
How much funding has Ikena Oncology raised over time?
Ikena Oncology has raised $393M.
-
Who are Ikena Oncology’s investors?
Atlas Venture, BVF Partners, Bristol-Myers Squibb, Celgene, and Citadel Enterprise Americas are 5 of 14 investors who have invested in Ikena Oncology.
-
Who are Ikena Oncology’s competitors?
SpringWorks Therapeutics, Marengo Therapeutics, Gilead, Adaptimmune Therapeutics, and AVEO Oncology are some of the 41 competitors of Ikena Oncology.
-
When was Ikena Oncology acquired?
Ikena Oncology was acquired on 25-Jul-2025.
-
Who acquired Ikena Oncology?
Ikena Oncology was acquired by ImageneBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
